MOLNUPIRAVIR EVA PHARMA 200 MG CAP

MOLNUPIRAVIR EVA PHARMA 200 MG CAP

Description:

MOLNUPIRAVIR EVA PHARMA 200 mg cap is a prescription antiviral medicine used for the treatment of mild to moderate coronavirus disease 2019 (covid-19) in adults at high risk of progressing to severe covid-19. It contains molnupiravir, a direct-acting oral antiviral that inhibits replication of sars-cov-2, the virus that causes covid-19. Produced by eva pharma, this medicine is supplied as oral capsules designed to be taken at home under medical supervision. Molnupiravir is not a substitute for covid-19 vaccination or booster doses but may help reduce viral load, shorten the duration of symptoms, and lower the risk of hospitalization when started early in the course of infection.

Indications:

• Treatment of mild to moderate covid-19 in adults with confirmed sars-cov-2 infection who are at increased risk for progression to severe disease, hospitalization, or death, as determined by a physician.
• Used in patients with early onset of symptoms (typically within 5 days of symptom start), such as fever, cough, sore throat, fatigue, headache, muscle pain, or loss of taste/smell, when confirmed or strongly suspected to be due to covid-19.
• Intended for patients who cannot access or are not suitable for other first-line antiviral therapies, according to local treatment guidelines and physician assessment.

Active Ingredients / Key Components:

• Molnupiravir – 200 mg per capsule.
• Excipients: Full list of inactive ingredients (capsule shell components, fillers, stabilizers) is not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.). Please refer to the official package leaflet for complete excipient details.

Dosage & Administration / How to Use:

• Recommended adult dose: 800 mg molnupiravir every 12 hours for 5 days, or as directed by your physician.
• This corresponds to four 200 mg capsules taken orally every 12 hours (total of 8 capsules per day) for a full 5-day course, for a total of 40 capsules.
• Swallow the capsules whole with a sufficient amount of water. Do not open, crush, or chew the capsules.
• May be taken with or without food, at approximately the same times each day to maintain consistent antiviral levels.
• Start treatment as soon as possible after a diagnosis of covid-19 and within 5 days of symptom onset, according to medical advice.
• Do not exceed the prescribed dose or extend the duration beyond 5 days unless specifically instructed by your doctor.
• If you miss a dose and it is within 10 hours of the scheduled time, take it as soon as you remember. If more than 10 hours have passed, skip the missed dose and take the next dose at the regular time. Do not double the dose.
• Use only under medical supervision. Not recommended for self-medication.

Clinical Benefits:

• Helps reduce replication of sars-cov-2 in the body, lowering viral load in the upper respiratory tract.
• May decrease the risk of progression from mild or moderate covid-19 to severe disease, hospitalization, or death in high-risk adults when started early.
• Oral capsule form allows convenient at-home treatment, potentially reducing the need for hospital-based intravenous therapy.
• Can contribute to faster clinical improvement of symptoms such as fever, cough, and fatigue in eligible patients, as part of comprehensive covid-19 management.

Warnings & Contraindications:

• Use only under the supervision and prescription of a qualified healthcare professional. Not intended for over-the-counter use.
• Not a substitute for covid-19 vaccination or booster doses. Continue to follow public health recommendations for vaccination, masking, and hygiene.
• Contraindicated in patients with known hypersensitivity to molnupiravir or any component of the formulation.
• Pregnancy: Molnupiravir is not recommended during pregnancy due to potential risk of harm to the fetus. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose, as advised by their doctor.
• Breastfeeding: Use with caution. Breastfeeding women should consult their doctor to weigh the potential benefits and risks, including whether to discontinue breastfeeding or avoid the medicine.
• Fertility and contraception: Men of reproductive potential may be advised to use effective contraception during treatment and for a period after the last dose, according to local guidelines and physician advice.
• Use with caution in patients with severe renal or hepatic impairment; data may be limited. Dose adjustment recommendations should follow official guidelines and physician judgment.
• Not authorized for use in patients requiring hospitalization for severe or critical covid-19 at the time of starting treatment, unless specifically directed by a specialist.
• Not recommended for use in children and adolescents under 18 years of age due to insufficient safety and efficacy data.
• Inform your doctor about all other medicines, supplements, or herbal products you are taking to assess potential interactions, even though clinically significant interactions are not widely reported.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as severe kidney disease, liver disease, immunosuppression, or other serious chronic illnesses.
• Keep out of reach of children.

Side Effects:

• Common side effects may include headache, dizziness, nausea, diarrhea, and fatigue. These are usually mild to moderate and transient.
• Less common side effects can include vomiting, abdominal discomfort, or rash.
• Serious adverse reactions are uncommon but may include signs of allergic reaction such as difficulty breathing, swelling of the face, lips, tongue, or throat, or severe skin reactions. Seek immediate medical attention if these occur.
• If you experience persistent or worsening symptoms, unusual bleeding, severe gastrointestinal symptoms, or any other concerning effects, contact your doctor promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date stated on the package. Store at or below the temperature specified in the official leaflet (exact temperature range not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.)).

Specifications:

• Active ingredient: Molnupiravir 200 mg per capsule.
• Product form: Hard capsules for oral use.
• Pack size: 40 capsules per pack (sufficient for a full 5-day treatment course at 800 mg every 12 hours, as prescribed).
• Intended user group: Adult patients as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.